TYK Medicines, Inc., a biopharmaceutical company that is about to enter the commercialization stage, today announced that it would participate in the 2026 Annual Meeting of the American Association for Cancer Research (AACR 2026), to be held in San Diego, USA, from April 17 to 22, 2026. During the meeting, TYK Medicines will present the research progress and results of 5 innovative drug projects in the form of posters, including TY-0609 (CDK4 inhibitor), TY-2699a (CDK7 inhibitor), TY-2719 (EGFR/FAK (PROTAC) inhibitor), PI3Kα (PI3Kα inhibitor), and TY-1054 (YAP-TEAD inhibitor). The 5 projects to be presented are innovative small molecule drug candidates that are all independently discovered and developed by TYK Medicines. Preclinical research results demonstrated that these molecules show significant potential in terms of efficacy, safety, or metabolic properties.

Information of the posters

Project: TY-0609 (CDK4 inhibitor)

• Title: Development of a novel selective CDK4 inhibitor for HR+/HER2- breast cancer
• Poster No.:1263
• Session: Targeting DNA Repair, Cell Cycle, and Tumor Metabolism
• Date: April 19, 2026
• Time: 2:00PM-5:00PM（PST）
• Location: Poster Section 49

Project: TY-2699a (CDK7 inhibitor)

• Title: A potent CDK7 inhibitor TY-2699a has the potential for combination with chemotherapy or immunotherapy in solid tumors
• Poster No.:3916
• Session: Molecular Targeted Therapy
• Date: April 20, 2026
• Time: 2:00PM-5:00PM（PST）
• Location: Poster Section 47

Project: TY-2719 (EGFR/FAK (PROTAC) inhibitor)

• Title: The EGFR-PROTAC molecule TY-2719 attenuates acquired resistance to 3rd generation EGFR TKIs and augments the efficacy of KRAS mutant inhibitors in solid tumors
• Poster No.:5171
• Session: Targeted Protein Degradation and Induced Proximity
• Date: April 21, 2026
• Time: 9:00AM-12:00PM（PST）
• Location: Poster Section 39

Project: PI3Kα (PI3Kα inhibitor)

• Title: Identification and characterization of pan-mutant selective PI3Kα inhibitors with the capability of PI3Kα H1047R protein degradation
• Poster No.:5130
• Session: New Ligands and Inhibitors
• Date: April 21, 2026
• Time: 9:00AM-12:00PM（PST）
• Location: Poster Section 38

Project: TY-1054 (YAP-TEAD inhibitor)

• Title: The selective YAP/TEAD inhibitor TY-1054 enhances the efficacy of KRAS inhibitors or Trop2-ADC in multiple solid tumors
• Poster No.:6494
• Session: Combination Targeted Therapy
• Date: April 21, 2026
• Time:2:00PM-5:00PM（PST）
• Location: Poster Section 42

ABOUT THE COMPANY

TYK Medicines is an international innovative biopharmaceutical company focusing on the research and development of next-generation kinase inhibitors to address unmet clinical needs in cancer treatment. Since its inception in 2017, TYK Medicines has developed more than ten innovative products, covering various stages from PCC to Phase III clinical trials. The Company is committed to providing patients with more effective and safer anti-tumor drugs.

FORWARD-LOOKING STATEMENT

The Company and the Company as referred to in this news make no representation or warranty, express or implied, as to the information released. Although the Company endeavors to ensure the accuracy of the information, it may contain inaccuracies or omissions. The information may not cover all relevant factors and different conclusions may be drawn due to different interpretation methods. Forecasts and opinions are speculative and are based on assumptions regarding future markets, customer behavior, and technological developments, and thus may be subject to significant errors. The information and opinions are as of the date of publication only and are subject to change at any time, and will not be updated for subsequent developments.

Neither the Company nor its affiliates, nor their respective directors, senior management, employees, consultants or representatives, shall be liable for any loss (including loss arising from negligence, misrepresentation, omission or otherwise) arising from the use of or reliance on the information herein, or any decision made based on such information.